{"id":"NCT02964247","sponsor":"Novo Nordisk A/S","briefTitle":"LIRA-ADD2SGLT2i - Liraglutide Versus Placebo as add-on to SGLT2 Inhibitors.","officialTitle":"LIRA-ADD2SGLT2i - Liraglutide Versus Placebo as add-on to SGLT2 Inhibitors","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2017-03-03","primaryCompletion":"2018-05-04","completion":"2018-05-08","firstPosted":"2016-11-16","resultsPosted":"2019-07-10","lastUpdate":"2020-11-17"},"enrollment":303,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Diabetes","Diabetes Mellitus, Type 2"],"interventions":[{"type":"DRUG","name":"liraglutide","otherNames":[]},{"type":"DRUG","name":"placebo","otherNames":[]}],"arms":[{"label":"liraglutide + SGLT2i ± metformin","type":"EXPERIMENTAL"},{"label":"liraglutide placebo + SGLT2i ± metformin","type":"PLACEBO_COMPARATOR"}],"summary":"The trial is conducted in Asia, Europe, North America and South America. The aim of the study is to compare the effect of liraglutide 1.8 mg/day versus placebo as add-on to an SGLT2 inhibitor with or without metformin on glycaemic control in subjects with type 2 diabetes mellitus.","primaryOutcome":{"measure":"Change in HbA1c","timeFrame":"Week 0, Week 26","effectByArm":[{"arm":"Liraglutide","deltaMin":-1,"sd":0.86},{"arm":"Placebo","deltaMin":-0.32,"sd":0.83}],"pValues":[{"comp":"OG000 vs OG001","p":"<.001"},{"comp":"OG000 vs OG001","p":"<.001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":8},"locations":{"siteCount":82,"countries":["United States","Brazil","India","Israel","Puerto Rico","Russia","United Arab Emirates"]},"refs":{"pmids":["31984646","34132018"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":5,"n":202},"commonTop":["Nausea","Diarrhoea","Decreased appetite","Vomiting","Constipation"]}}